Are you a researcher, company or non-profit organisation interested in transforming innovative research into real-world impact?
Contact us
for any university-industry-society interaction
Recent news
Precirix Receives FDA Green Light for Novel Cancer Therapy
VUB spin-off Precirix announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CAM-FAP-Ac-225. This significant achievement paves the way for Precirix to begin a Phase 1 clinical trial for patients battling FAP-positive tumors.
Swave Photonics raises €6M for holographic display technology
Swave Photonics, a spin-off from imec and VUB, has raised an additional €6 million in Series A funding. This follow-on investment will accelerate the development of Swave's innovative holographic display technology for Spatial + AI Computing.
Animab secures €10M for antibiotic-free animal health solution
Animab, a VUB-VIB-UGent spin-off, has secured €10 million in Series B funding to launch its innovative antibiotic-free solution for piglet health, tackling antimicrobial resistance.
In the picture
ERIS
The ERIS team proudly announces that the ERIS consortium has received an EU grant. Prof. dr. De Asmundis, programme director of the postgraduate Training in Cardiac Electrophysiology & Pacing, will coordinate this project for VUB.
FC3
The ERIS team proudly announces that the FC3 consortium has received an EU grant. Prof. Hugo Thienpont, Director of Brussels Photonics at Vrije Universiteit Brussels, will coordinate this project for VUB.
Acclimate
The ERIS team proudly announces that the ACCLIMATE consortium has received an EU grant. Prof. Sebastian Oberthür, Director of VUB's Research Centre for Environment, Economy and Energy, will coordinate this project for VUB.
